Study of Dasatinib in Patients with CML
This clinical trial will assess the safety of dasatinib and whether this drug can help control CML in chronic phase. The study is split into two arms, with patients starting on a dosage of either 100 mg once daily or 50 mg twice daily of dasatinib.
Study Type: Interventional
Age/Sex Requirements: 16 years+ (None)
Sponsor: MD Anderson Cancer Center
Purpose: This clinical trial will assess the safety of dasatinib and whether this drug can help control CML in chronic phase. The study is split into two arms, with patients starting on a dosage of either 100 mg once daily or 50 mg twice daily of dasatinib. The primary outcome measure will be the time to first molecular response prior to 12 months.
Related Videos
Related Content
